Pharmacokinetics of amifostine and its metabolites in patients

European Journal of Cancer Part A

Volumn 33, Issue 9, 1997, Pages 1425-1429

  Korst, A E C ^a   Eeltink, C M ^a   Vermorken, J B ^a   Van Der Vijgh, W J F ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Amifostine; Disulphides; Ethyol; Pharmacokinetics; WR 1065; WR 2721

Indexed keywords

2 (3 AMINOPROPYLAMINO)ETHANETHIOL; AMIFOSTINE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DEXAMETHASONE; DISULFIDE; LORAZEPAM; ONDANSETRON; THIETHYLPERAZINE MALEATE;

ADULT; ANIMAL MODEL; ARTICLE; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE TIME EFFECT RELATION; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG METABOLISM; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MOUSE; NAUSEA; NEPHROTOXICITY; NONHUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; VOMITING;

ADULT; AMIFOSTINE; ANTINEOPLASTIC AGENTS; CARBOPLATIN; CISPLATIN; DISULFIDES; DRUG THERAPY, COMBINATION; FEMALE; HALF-LIFE; HUMANS; MALE; MERCAPTOETHYLAMINES; MIDDLE AGED;

EID: 0030766407     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)00138-X     Document Type: Article

References (21)

1. Treskes M, Boven E, Holwerda U, Pinedo HM, Van der Vijgh WJF. Time dependence of the selective modulation of cisplatin-induced nephrotoxicity by WR-2721 in the mouse. Cancer Res 1992, 52, 2257-2260.
2. Treskes M, Boven E, Van de Loosdrecht AA, et al. Effects of the modulating agent WR2721 on myelotoxicity and antitumor activity in carboplatin-treated mice. Eur J Cancer 1994, 30A, 183-187.
3. Van der Vijgh WJF, Peters GJ. Protection of normal tissues form the cytotoxic effects of chemotherapy and radiation by amifostine (ethyol): preclinical aspects. Semin Oncol 1994, 21, 2-7.
4. Brown DQ, Graham WJ, Mackenzie LJ, Pittock JW, Shaw LM. Can WR-2721 be improved upon? Pharmacol Ther 1988, 39, 157-168.
5. Calabro-Jones PM, Aguilera JA, Ward JF, Smoluk GD, Fahey RC. Uptake of WR-2721 derivatives by cells in culture: identification of the transported form of the drug. Cancer Res 1988, 48, 3634-3640.
6. Shaw LM, Glover D, Turrisi A, et al. Pharmacokinetics of WR-2721. Pharmacol Ther 1988, 39, 195-201
7. Utley JF, Seaver N, Newton GL, Fahey RC. Pharmacokinetics of WR-1065 in mouse tissue following treatment with WR-2721. Im J Radiat Oncol Biol Phys 1994, 10, 1525-1528.
8. Shaw LM, Bonner HS, Brown DQ. Metabolic pathways of WR-2721 (Ethyol, amifostine) in the BALB/c mouse. Drug Metab Dispos 1994, 22, 895-902.
9. Shaw LM, Turrisi AT, Glover DJ, et al. Human pharmacokinetics of WR-2721. Im J Radiat Oncol Biol Phys 1986, 12, 1501-1504.
10. Shaw L, Bonner H, Nakashima H, Lieberman R. Pharmacokinetics of amifostine in cancer patients: evidence for saturable metabolism. Proc Am Soc Clin Oncol 1994, 13, 144.
11. Shaw L, Bonner H, Schuchter L, Schiller JH, Nakashima H, Lieberman R. Population pharmacokinetics of amifostine in cancer patients. Proc Am Soc Clin Oncol 1996, 15, 478.
12. Mangold DJ, Miller MA, Huelle BK, et al. Disposition of the radioprotector ethiofos in the rhesus monkey: influence of route administration. Drug Metab Dispos 1989, 17, 304-310.
13. Mangold DJ, Huelle BK, Miller MA, et al. Pharmacokinetics and disposition of WR-1065 in the rhesus monkey. Drug Metab Dispos 1990, 18, 281-287.
14. Korst AEC, Gall HE, Vermorken JB, Van der Vijgh WJF. Pharmacokinetics of amifostine and its metabolites in the plasma and ascites of a cancer patient. Cancer Chemother Pharmacol 1996, 39, 162-166.
15. Korst AEC, Snel J, Kedde MA, Van der Vijgh WJF. A sensitive HPLC-ECD assay for amifostine and its metabolites in plasma. Proc Int Symp Column Chromatogr Rel Tech 1995, 19, 225.
16. Korst AEC, Vermorken JB, Van der Vijgh WJF. An HPLC-ECD assay for the combined measurement of amifostine, WR 1065 and the disulfides in plasma. J Chromatogr B, in press.
17. Ryan SV, Carrithers SL, Parkinson SJ, et al. Hypotensive mechanisms of amifostine. J Clin Pharmacol 1996, 36, 365-373.
18. Turrisi AT, Glover DJ, Hurwitz S, et al. Final report of the phase I trial of single-dose WR-2721 [S-2-(3-aminopropylamino)ethylphosphorothioic acid]. Cancer Treat Rep 1986, 70, 1389-1393.
19. Treskes M, Holwerda U, Klien I, Pinedo HM, Van der Vijgh WJF. The chemical reactivity of the modulating agent WR 2721 (ethiofos) and its metabolites with the antitumor agents cisplatin and carboplatin. Biochem Pharmacol 1991, 42, 2125-2130.
20. Korst AEC, Boven E, Van der Sterre MLT, Fichtinger-Schepman AMJ, Van der Vijgh WJF. Influence of single and multiple doses of amifostine on the efficacy and the pharmacokinetics of carboplatin in mice. Br J Cancer in press.
21. Korst AEC, Van der Sterre MLT, Eeltink CM, Fichtinger-Schepman AMJ, Vermorken JB, Van der Vijgh WJF. Pharmacokinetics of carboplatin with and without amifostine in patients with solid tumors, Clin Cancer Res. in press.